JoVE Logo
Faculty Resource Center

Sign In

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells

DOI :

10.3791/64025-v

12:14 min

June 2nd, 2022

June 2nd, 2022

2,015 Views

1Umeå Centre for Molecular Medicine, Umeå University, 2Department of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences

The CAM-Delam assay to evaluate the metastatic capacity of cancer cells is relatively fast, easy, and cheap. The method can be used for unraveling the molecular mechanisms regulating metastasis formation and for drug screening. An optimized assay for analyzing human tumor samples could be a clinical method for personalized cancer treatment.

Tags

CAM Delam Assay

-- Views

Related Videos

article

Transmitochondrial Cybrid Generation Using Cancer Cell Lines

article

Optimization of Performance Parameters of the TAGGG Telomere Length Assay

article

Shear Assay Protocol for the Determination of Single-Cell Material Properties

article

Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

article

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

article

A Three-Dimensional Technique for the Visualization of Mitochondrial Ultrastructural Changes in Pancreatic Cancer Cells

article

Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures

article

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

article

Author Spotlight: Demonstrating Systematic Endobronchial Ultrasound to New Endoscopists

article

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved